InsuLife is a Norwegian company aiming at developing and bringing the unparalleled investigational ILS-2501 apply-on-the-skin based insulin to market. This includes the carrying out of any and all necessary product studies and authorization activities.

ILS-2501 will represent an international innovation and paradigm shift. Insulin in apply-on-the-skin form has the potential to fulfill a need for people with diabetes who want to avoid needles and to take insulin in the most practical way.

There is no transdermal apply-on-the-skin insulin in the global pharmaceutical market today. InsuLife are developing a novel product with delivery of apply-on-the-skin insulin which will be easy form of administration and efficacy is expected to be comparable to the traditional subcutaneous injections.

The Future of Insulin Delivery
ILS-2501 aims to be the first transdermal apply-on-the-skin Insulin. Applied directly onto the skin, ILS-2501 eliminates the use of needles. The target of this breakthrough product:
Eliminates multiple injections per day
Potential for better patient compliance
Utilizes unmodified human insulin, a “commodity” drug product enabling cost competitiveness
Shows strong indication of stability in room temperature, - no need for refrigeration

InsuLife

Org chart

Teams

Offices